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Abstract 
Introduction Of all malignant processes of the oral mucosa, 0.5% are malignant 
melanomas. Because of late diagnosis, pattern of growth, close proximity to the bone 
(particularly in palatinal localizations), and the correlated infiltration, malignant 
melanomas have a bad prognosis. 
Patients and methods In this retrospective study, six cases of patients with oral 
mucosal malignant melanoma are evaluated, and a critical review of the literature is 
presented. The female to male proportion was 1:1 with an average age of 60.2 years; 
all patients were treated between January 1999 and July 2007. A neck dissection 
was performed on two patients because of clinically positive lymph nodes; one 
patient received interleukin 2 therapy and three patients received postoperative 
radiotherapy. Two male patients died. 
Conclusion We recommend biopsy on every growing lesion, pigmented or non-
pigmented, for the required diagnosis and, in cases of malignant melanoma, wide 
excision as a second step. Neck dissections should be performed in patients with 
clinically positive lymph nodes. Concerning interleukin 2 therapy, further studies 
should be performed in order to evaluate a routine application. 
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Introduction 
Melanoma of the mucosa is very rare, presenting in only 1.3% of all melanomas [1], 
and it is especially rare in patients below the age of 30 years [2]. The peak age is 
between 65 and 79 years [3]. No risk factors for intraoral lesions have been clearly 
identified to date [4]. For mucosal melanomas, distribution on the head and neck 
occurs in 55.4% of cases, followed by anal/rectal (23.8%), female genital tract (18%), 
and urinary tract sites (2.8%)[1]. The most frequently affected sites in the oral cavity 
are the maxillary gingival and the palate [5, 6], and they are more commonly affected 
in Japan and Africa than in Western countries [2, 7, 8]. The development of oral 
malignant melanomas (OMM) and the function of melanocytes in the oral mucosa 
have still not been clearly identified. One reason for the rare appearance of OMM 
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might be the low concentration of melanocytes in the oral mucosa. In single tissue 
sections of the gingiva, the ratio is one melanocyte to 15 keratinocytes, whereas in 
the skin of the cheek, the ratio is 1:4 and in the trunk 1:14 [5]. Melanocytes migrate 
much less frequently to endodermally derived mucosa—e. g., nasopharynx, larynx, 
esophagus, or tracheobronchial tree; therefore, mucosal malignant melanomas are 
rare in these locations [3]. Concerning the difference between oral melanomas 
arising in the squamous or the respiratory (sinonasal) mucosa, the clinical outcome is 
slightly, but not significantly, worse in sinonasal melanomas. Prasad ML et al [9] 
studied the difference in clinical behaviour of 36 oral versus 59 sinonasal malignant 
melanoma. The latter demonstrates more aggressive morphologic features, but 
prognosis remains similar in both groups. It is striking, however, that in the squamous 
mucosa, men are affected 3.5 times more frequently than women.[9]  
Three criteria for the diagnosis of primary oral melanoma were proposed by 
Greene et al. [10]: (1) demonstration of malignant melanoma in the oral mucosa, (2) 
presence of “junctional activity” in the lesion, (3) and inability to show malignant 
melanoma at another primary site. But junctional activity is now seen as an unreliable 
indicator that the lesion is primary, because melanoma metastasis can also involve 
the epithelium junction.  
For determining the stage of cutaneous malignant melanomas, Breslow`s 
depth of penetration and Clark`s level of invasion, which correspond to the regional 
lymph node status and presence/absence of metastasis, have been used. 
Furthermore, two different growth patterns have been mentioned: (1) a radial growth 
phase that tends not to invade the underlying reticular corion, but is associated with 
metastasis and (2) the vertical growth pattern, invasive and growing before 
metastasis can occur [3]. For mucosal malignant melanomas, Clark`s level of 
invasion cannot be applied because of missing histological landmarks like papillary 
and reticular dermis [11]; in addition, oral malignant mucosas have a radial growth 
phase [2] with early metastasis. 
Therefore, the purpose of this study was to determine the initial symptoms, 
localization, stage, presence of regional or distant metastases and treatment. 
 
Patients and Methods 
The records of all patients with mucosal malignant melanoma from January 
1999 and July 2007, six patients (three females, three males) treated at the Clinic for 
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Craniomaxillofacial and Oral Surgery, University Hospital Zurich, were systematically 
reviewed. Criteria for inclusion were histologically proven primary malignant 
melanoma of the oral cavity. Criteria for exclusion were inadequate information, 
secondary oral malignant melanoma and recurrent disease. Data of site of tumor, 
histopathology, stage, presence of regional or distant metastases, treatment, 
recurrence and outcome were analyzed. 
All patients had incisional biopsy performed before definitive treatment.  
 
Results 
Age, sex, and primary sites 
 
Subjects involved were three female and three male patients with an average age of 
60.2 years. All patients revealed an OMM of the maxilla. The initial clinical 
presentation is listed in Table 1. 
 
Initial symptoms, stages, and course of the disease 
 
The primary symptoms were pigmentation in three cases and painless swelling in 
three cases (Fig. 1). No bleeding or pain as a first symptom was reported. In all 
patients, a biopsy was first performed, and wide excision followed as a second step. 
Two patients presented primary positive lymph nodes, so a neck dissection was 
immediately performed. 
 
Histological findings 
 
In two (with clinical T1 status) out of the for patients, the primary incisional biopsy 
was taken alio loco and a clear determination of infiltration depth was impossible, but 
in one of the two patients a superficial spreading growth pattern (patient 6 in Table 2) 
was observed. Concerning the melanoma marker, HMB-45, S-100 protein, and 
tyrosinase were used. One case was an amelanotic melanoma. 
The tumors consisted of highly atypical melanocytes with partial pigmentation. 
They showed focal necrosis and infiltration of the gnathic bones (Fig. 2a and b). 
Three of the cases were composed of spindle cell melanomas.  
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Treatment results 
 
Two (male) patients out of six died because of the malignant melanoma. After 3 
months, one of these two patients had developed lung metastases; he received 
interleukin 2 therapy after metastasis, but he died. One male patient had a 
recurrence. 
Three of the six patients underwent directly postsurgical radiation therapy. 
None of the patients received chemotherapy (Table 2). 
 
Discussion 
 
Clinically, OMM can be devided into five types: (1) pigmented nodular, (2) 
nonpigmented nodular, (3) pigmented macular, (4) pigmented mixed, and (5) 
nonpigmented mixed type [12]. Differential diagnosis include drug-, disease-, 
pregnancy-, or smoking-associated melanosis, oral melanotic maculae, Kaposi’s 
sarcoma, physiologic pigmentation, melanoacanthoma, and nevus.  
 
Outcome 
 
It is generally accepted that the outcomes for oral malignant melanomas are worse 
than those for the cutaneous form. About 10% of oral melanomas are amelanotic, 
and more than 95% of the lesions are anti-S-100 antigen positive, with more specific 
markers including HMB 45, Melan-A, and antityrosinase [13]. These amelanotic 
malignant melanomas have a worse prognosis than other kinds because of the 
delays in establishing the correct diagnosis and also because they are thought to be 
more aggressive than pigmented melanomas [8]. One of the two patients that died 
had an amelanotic malignant melanoma (patient 2 in Table 2) and presented early 
lung metastases. 
Rogers et al. [14] reported that 50% of all patients with oral melanoma had 
regional lymph node metastases. In our patients, one with OMM revealed directly 
positive lymph nodes, so a neck dissection was performed. We did no elective neck 
dissection on N0 tumors. Lens et al. [15] did a meta-analysis of 1,522 cases and 
showed that there is no significant overall survival benefit for patients undergoing 
elective neck dissections. 
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There are different reasons for aggressive behaviour in oral malignant 
melanomas. One reason is, on the one hand, the presence of the vertical more 
aggressive growth (nodular) with invasion of the underlying submucosa and, on the 
other hand, the radial growth (superficial spreading) phase that is characterized by 
early metastasis [5]. In the present study, one patient revealed a superficial 
spreading growth pattern (patient 6 in Table 2) with primary T1 status and early 
metastases. Furthermore, the diagnosis can be delayed because most of the oral 
forms are painless in the early stages and do not reveal ulceration like the oral 
squamous cell carcinomas. In the present study, no patient had ulceration, bleeding, 
or pain as a first symptom. However, the overall 5-year survival rate is <30% [16-18].  
Another important prognostic factor is the early metastasis in oral malignant 
melanomas because, in certain localizations like the palate, the tumor does not need 
to invade very deeply before reaching the bone, and radiologic evidence of bony 
erosions has been associated with early hematogeneous spread [2]. In our study 
population, all patients had malignant melanomas in the upper jaw. 
 In the oral cavity, wide excisions are limited because of the anatomical 
structures; therefore, surgical results cannot always be compared between 
cutaneous and oral forms.  The average age of patients with OMM in our study 
population was 60.2 years of age; the age is, in general, higher in comparison to 
squamous cell carcinomas. The highest incidence in the group is between 40 and 70 
years as reported [13, 19]. Therefore, the higher age also plays an important role in 
the outcome. 
 Bad prognostic factors, in general, correlate with tumor thickness and 
ulceration. Several studies also showed that male patients had a worse prognosis; 
the two patients that died and the one patient with a recurrence were men. In 
general, malignant melanomas are found almost three times more frequently in men 
than in women, though in the present retrospective study the male-female distribution 
was 1:1. 
Gingival melanoma has a slightly greater 5-year survival rate than that for 
palatinal melanoma, with a longer median survival period (46 months vs. 22 months). 
Nodal involvement with oral melanoma reduces median survival substantially from 46 
months to only 18 months [5]. In the literature, different survival times are mentioned 
for OMM. Chang et al. [1] reported a 5-year disease-specific survival for OMM of 
31.7%. Meleti et al. [7] reported a 5-year survival of only 15%. 
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To sum up, the factors that are significant in lower disease-specific survival 
rates are primary high clinical stage, tumor thickness greater than 5 mm, presence of 
vascular invasion, absence of melanosis, and development of lymph node or distant 
metastases. 
 
Excisional versus incisional biopsy 
  
Cytological tests on brushed samples seem not to be reliable [4] and are, like fine- 
needle aspiration, contraindicated [3]. Concerning biopsies in malignant melanomas, 
dissemination of malignant cells in the tissue, blood, or lymphatic stream is 
discussed. Bong et al. [20], in a retrospective study of 265 patients having an 
incisional biopsy of cutaneous melanoma and 496 control cases of excisional biopsy, 
reported no correlation of malignant spreading; and Lederman et al. [21] reported 
similar results. 
One patient had been lasered before because of pigmentation. We 
recommend that any growing lesion, pigmented or non-pigmented, should be 
biopsied without delay for a diagnosis. 
 
Treatment 
 
Most authors advocate wide local excision of the tumor [4, 22]. Oral malignant 
melanomas are not very radiosensitive, but postoperative radiotherapy is generally 
recommended in multiple positive nodes, in extranodal spread, and in poor 
prognostic pathologic features [7, 23]. 
The goal of immunotherapy is an activation of immune-competent cells in the 
tumor defense when, e.g., interferon or interleukin are administered [24]. Verma et al. 
[25] were able to show in a review that a high dose of interferon is associated with a 
significant improvement in disease-free survival and a reduction of 2-year mortality. 
Concerning interleukin 2 therapy, between 1985 and 2006 Petrella et al. [26] 
reviewed non-comparative phase II trials of high-dose, single-agent interleukin 2 with 
a response rate of 10-33% and with a complete response rate from 0-15%. The one 
patient that was treated with interleukin 2 in the present study already had lung 
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metastasis and died. There is still a need for further investigations concerning 
immunotherapy in this particular group of malignancies.  
 
Conclusion 
 
Every growing lesion, pigmented or non-pigmented, requires a diagnosis; therefore, 
we recommend biopsy and, because of anatomical limits, wide excision as a second 
step. In cases of clinically positive lymph nodes, a neck dissection should be done 
immediately. In patients with negative lymph nodes, an elective neck dissection 
should not be offered directly. Despite the improvement of surgical techniques and 
the introduction of new chemotherapeutic agents, prognosis of this malignancy 
remains poor. 
 
Competing interests The authors declare that they have no competing interests. 
 
9 
 
 
Figure 1: Painless swelling as a first symptom  
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Figure 2a: Melanoma infiltrating the maxillary bone (arrow), H&E x100.  
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Figure 2b: Melanoma cells positive for HMB-45 (clone HMB-45, 1:50, DAKO, x200). 
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gender male 3 
  female 3 
     
localisation laterial maxillary alveolus 4 
  anterior maxilla 2 
     
T status T1 2 
  T2 1 
  T3 0 
  T4 3 
     
N status No 5 
  N1 0 
  N2a 0 
  N2b 0 
  N2c 1 
  N3 0 
     
Metastases M0 6 
  M1 0 
 
Table 1: Initial clinical presentation 
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patient sex cTNM treatment Local 
recurrence 
metastases survival follow-up time 
1 m T4N0M0 resection, RT - 1. skin metastases 
2. recurrence (skin) 
3. involvement of skull base 
 
DOD 12 months 
2 m T3N2c0o resection, 
bilat.neck 
dissection, RT 
Local 
recurrence 
(17 months) 
1. ileum metastases 
2. pulmonary and mesenterial metastases 
DOD 9 months 
3 f T4N0M0 resection, RT - - alive, tu-free 32 months 
4 f T1N0M0 resection - metastases lower eyelid alive, tu-free 42 months 
5 f T4N0M0 resection - pulmonary metastasis palliative 26 months 
6 m T1N0M0 resection - 1. contralateral cervical lymph node 
metastasis 
2. cheek metastasis 
3. cervical lymph nodes metastasis 
4. pulmonary, mediastinal, liver 
metastases 
palliatve 13 months 
 
 
Table 2: Initial Staging, treatment and outcome of the presented patients (DOD= dead of disease) 
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